More on IBRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $10.00 |
|
|||
| Open | $10.02 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $10.02 | ||||
| Day Low | $9.02 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 21,507,714 | ||||
- ImmunityBio reports 3-year bladder preservation data for Anktiva plus BCG
- ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Pap
- H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)
- Form 8-K ImmunityBio, Inc. For: Oct 14
- Immunitybio Inc (IBRX) PT Raised to $14 at Jefferies
- FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
- FDA expands Anktiva approval to include papillary-only bladder cancer
- ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
- Form 4 ImmunityBio, Inc. For: Oct 05 Filed by: Simon Barry J.
- Form 4 ImmunityBio, Inc. For: Oct 02 Filed by: Cohen Cheryl
Entities mentioned with IBRX
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- S3 | View Related Stories »
- Show More...
